220 related articles for article (PubMed ID: 19330716)
1. Splicing therapeutics in SMN2 and APOB.
Khoo B; Krainer AR
Curr Opin Mol Ther; 2009 Apr; 11(2):108-15. PubMed ID: 19330716
[TBL] [Abstract][Full Text] [Related]
2. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2.
Cartegni L; Hastings ML; Calarco JA; de Stanchina E; Krainer AR
Am J Hum Genet; 2006 Jan; 78(1):63-77. PubMed ID: 16385450
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
4. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
5. Splicing-Correcting Therapy for SMA.
Wan L; Dreyfuss G
Cell; 2017 Jun; 170(1):5. PubMed ID: 28666123
[TBL] [Abstract][Full Text] [Related]
6. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy.
Hastings ML; Berniac J; Liu YH; Abato P; Jodelka FM; Barthel L; Kumar S; Dudley C; Nelson M; Larson K; Edmonds J; Bowser T; Draper M; Higgins P; Krainer AR
Sci Transl Med; 2009 Nov; 1(5):5ra12. PubMed ID: 20161659
[TBL] [Abstract][Full Text] [Related]
7. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).
Hofmann Y; Lorson CL; Stamm S; Androphy EJ; Wirth B
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9618-23. PubMed ID: 10931943
[TBL] [Abstract][Full Text] [Related]
8. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.
Kashima T; Manley JL
Nat Genet; 2003 Aug; 34(4):460-3. PubMed ID: 12833158
[TBL] [Abstract][Full Text] [Related]
9. Cell-Based Therapy for Spinal Muscular Atrophy.
Han F; Ebrahimi-Barough S; Abolghasemi R; Ai J; Liu Y
Adv Exp Med Biol; 2020; 1266():117-125. PubMed ID: 33105498
[TBL] [Abstract][Full Text] [Related]
10. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.
Singh NK; Singh NN; Androphy EJ; Singh RN
Mol Cell Biol; 2006 Feb; 26(4):1333-46. PubMed ID: 16449646
[TBL] [Abstract][Full Text] [Related]
11. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.
Singh NN; Luo D; Singh RN
Methods Mol Biol; 2018; 1828():415-437. PubMed ID: 30171557
[TBL] [Abstract][Full Text] [Related]
12. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
Madocsai C; Lim SR; Geib T; Lam BJ; Hertel KJ
Mol Ther; 2005 Dec; 12(6):1013-22. PubMed ID: 16226920
[TBL] [Abstract][Full Text] [Related]
13. Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy.
Marasco LE; Dujardin G; Sousa-Luís R; Liu YH; Stigliano JN; Nomakuchi T; Proudfoot NJ; Krainer AR; Kornblihtt AR
Cell; 2022 Jun; 185(12):2057-2070.e15. PubMed ID: 35688133
[TBL] [Abstract][Full Text] [Related]
14. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence.
Marquis J; Meyer K; Angehrn L; Kämpfer SS; Rothen-Rutishauser B; Schümperli D
Mol Ther; 2007 Aug; 15(8):1479-86. PubMed ID: 17505471
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
Singh NN; Lee BM; DiDonato CJ; Singh RN
Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
[TBL] [Abstract][Full Text] [Related]
16. Evolving concepts on human SMN pre-mRNA splicing.
Singh RN
RNA Biol; 2007; 4(1):7-10. PubMed ID: 17592254
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
[TBL] [Abstract][Full Text] [Related]
18. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
[TBL] [Abstract][Full Text] [Related]
19. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain.
Sumner CJ; Crawford TO
J Clin Invest; 2018 Aug; 128(8):3219-3227. PubMed ID: 29985170
[TBL] [Abstract][Full Text] [Related]
20. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review.
Nakevska Z; Yokota T
Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
